Prevention of Recurrent Rhinopharyngitis in At-Risk Children in France: A Cost-Effectiveness Model for a Nonspecific Immunostimulating Bacterial Extract (OM-85 BV)

PharmacoEconomics

Volumn 21, Issue 14, 2003, Pages 1053-1068

  Pessey, Jean Jacques ^a   Mégas, Françoise ^b   Arnould, Benoît ^b   Baron Papillon, Florence ^b  

^a CHU RANGUEIL   (France)

^b MAPI VALUES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LYSATE; BRONCHO VAXON; IMMUNOSTIMULATING AGENT; IMOCUR;

ARTICLE; CHILD; CLINICAL TRIAL; COST OF ILLNESS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; FRANCE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; MODEL; PRIORITY JOURNAL; PROBABILITY; RECURRENT INFECTION; RHINOPHARYNGITIS; SENSITIVITY ANALYSIS;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ANTI-INFECTIVE AGENTS; BACTERIA; CELL EXTRACTS; CHILD; CHILD, PRESCHOOL; COMMON COLD; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; FRANCE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; RECURRENCE; RISK FACTORS;

EID: 0141889948     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321140-00005     Document Type: Article

References (29)

1. Viral diseases: the common cold. In: The Merck manual. Available from URL: http://www.merck.com/pubs/mmanual/section13/chapter162/162b.htm [Accessed 2003 Jul 1]
2. Conférence de consensus en thérapeutique anti-infectieuse, 16/ 6/1996 (Lyon). Les infections ORL (texte long). Médecine et Maladies Infectieuses 1997; 27 spécial: 341-54
3. Agence du médicament. Antibiothérapie par voie générale en pratique courante: rhinopharyngite aiguë. Paris: Janvier, 1999
4. Monographie Imocur® enfant. Dictionnaire Vidal: OVP Editions du Vidal 76ème ed. Paris, 2000
5. Mauël J. Stimulation of immunoprotective mechanisms by OM-85 BV: a review of results from in vivo and in vitro studies. Respiration 1994; 61 Suppl. 1: 8-15
6. Puigdollers JH, Serma GR, Hernandez del Rey I. Immunoglobulin production in man stimulated by an orally admintered bacterial lysate. Respiration 1980; 40: 142-9
7. Duchow J, Marchant A, Delville JP, et al. Up-regulation of adhesion molecules induced by Broncho-Vaxom on phagocytic cells. Int J Immunopharmacol 1992; 14: 761-6
8. Paupe J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration 1991; 58: 150-4
9. Zagar S, Loëfler-Badzek D. Broncho-Vaxom® in children with rhinosinusitis: a double-blind clinical trial. ORL J Otorhinolaryngol Relat Spec 1988; 50: 397-404
10. Maestroni GJM, Losa GA. Clinical and immunobiological effects of an orally adminitrated bacterial extract. Int J Immunopharmacol 1984; 6 (2): 111-7
11. Collet JP, Boissel JP. OM-85 BV: primary versus secondary prevention. Respiration 1994; 61 Suppl. 1: 20-3
12. Collet JP, Ducruet T, Kramer MS, et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. Pediatr Infect Dis J 1993; 12: 648-52
13. Panel dorema hiver 1998-1999. Paris: IMS Health France, 1999
14. Fagnani F, Lafuma A, Pechevis M, et al. Evaluation du retentissement économique et social des infections respiratoires et ORL récidivantes de l'enfant. Santé Publique 1995; 7 (3): 247-56
15. Van Cauwenberge P, Berdeaux G, Morineau A, et al. Use of diagnostic clusters to assess the economic consequences of rhino-pharyngitis in children in Italy and France during the winter. Clin Ther 1999; 21 (2): 404-21
16. Banz K, Schwicker D, Thomas AM. Economic evaluation of Immunoprophylaxis in children with recurrent ear, nose and throat infections. Pharmacoeconomics 1994; 6 (5): 464-77
17. Reinert P, Morales M, Brin S. Evaluation d'un traitement préventif par RU 41740 (Biostim®) des infections rhinopharyngé es récidivantes de l'enfant. Ann Pediatr (Paris) 1995; 42 (7): 454-60
18. Le Fur P, Sermet C. Rhinopharyngites et antibiothérapie en 1992. Paris: Credes, 1995: 1105
19. Mabriez JC, Dominjon X, Poussardin X, et al. Place de l'antibiothérapie dans les infections ORL et respiratoires de l'enfant de 0 à 7 ans. Etude régionale inter-régime 1996. Lyon: Assur-ances Maladie, 1997
20. Floret D. Récentes acquisitions épidémiologiques et thérapeutiques des infections respiratoires de l'enfant en crèche. Pédiatrie 1991; 46: 14-7
21. Echelle nationale de coûts relatifs par groupes homogènes de malades (GHM). Paris: Ministère de l'Emploi et de la Solidarité. Bulletin Officiel No 99/2bis, 1999
22. Cohen R. Enquête nationale sur les critères de prescription d'une antibiothérapie dans les rhinopharyngites en pédiatrie de ville. Ann Pediatr (Paris) 1992; 39 (3): 195-201
23. Leizorowicz A. Diagnosis and management of acute otitis media in children: result from a national survey. Can J Infect Dis 1995; 6: 359C
24. Yawn BP, Yawn RA, Lydick E. The relative community burden of otitis media and varicella. Clin Ther 1996; 18 (5): 877-86
25. Wald ER. Sinusitis in children. N Engl J Med 1992; 326 (5): 319-29
26. Heikkinen T, Ruuskanen O. Temporal development of acute otitis media during upper respiratory tract infection. Pediatr Infect Dis J 1994; 13 (7): 659-61
27. Wald ER, Guerra N, Byers C. Upper respiratory tract infections in young children: duration and frequency of complications. Pediatrics 1991; 87 (2): 129-33
28. Cohen R, Boucherat M, Doit C, et al. Treatment failure in otitis media: an analysis. J Chemother 1994; 6 Suppl. 4: 17-22
29. Berdeaux G, Lafuma A, Perruchet AM, et al. Cost effectiveness of immunoprophylaxis in the prevention of recurrent infectious rhinitis in adults. Pharmacoeconomics 1998; 14 (3): 313-22